Positives

• A case series of post-COVID neuropsychiatric patients showed dramatic improvement of all symptoms after weekly adalimumab 40 mg for one month PMC.
  
  
• Authors noted it was the first case series demonstrating an anti-TNF role in post-COVID syndrome PMC.
  
  

Negatives

• Adalimumab significantly impaired SARS-CoV-2 antibody responses in over 11,000 biologic-treated patients PMC.
  
  
• A psoriasis flare-up case occurred shortly after COVID infection while on biologic therapy PMC.
  
  

Hurdles & Side Effects

• TB and hepatitis B screening, plus injection training, are required before initiation Humira.
  
  
• Off-label Long COVID use is not covered by insurance and self-pay runs thousands per month Springer.